HRTX News and Press, Heron Therapeutics Inc. From 06/30/22

Heron Therapeutics ( NASDAQ: HRTX ) on Thursday said it was planning to reduce its employee headcount by 34% as part of a restructuring and cost reduction plan. The plan also includes reductions and reallocations to the company's overall sales, general and administrati...

Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability PR Newswire - Changes result in annualized cost savings of $43M , extending the cash runway; Company is continuing to reduce exter...

The most heavily shorted names have been rallying off their lows in the past several days. On a relative basis, the 100 most heavily shorted stocks versus the Russell 3,000 have broken out of the downtrend that has been in place since the height of the meme stock mania in January 2021...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty PR Newswire SAN DIEGO , June 14, 202...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference PR Newswire SAN DIEGO , May 26, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patie...

Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting PR Newswire - New interim data from Phase 2 study suggests ZYNRELEF was well-tolerated and may effectively manage postpartum pain and minimize p...

Heron Therapeutics, Inc. (HRTX) Q1 2022 Results Conference Call May 09, 2022 04:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - Chairman and CEO John Poyhonen - President and Chief Commercial Officer Kimberly Manhard - EVP, Drug Development and Board Director Conferen...

Heron Therapeutics press release (NASDAQ:HRTX): Q1 GAAP EPS of -$0.63 misses by $0.15. Revenue of $23.46M (+17.2% Y/Y) beats by $0.85M. For further details see: Heron Therapeutics GAAP EPS of -$0.63 misses by $0.15, revenue of $23.46M beats by $0.85M